No Data
No Data
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy
Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...
Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density
Express News | Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge
Express News | Atossa Therapeutics - 1 Mg Dose Reduced Mbd by 17.3 Percentage Points, 2 Mg Dose by 23.5 Vs Minimal Change in Placebo Group of 0.27